Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jana Sänger"'
Purpose: Dasatinib and nilotinib are active in imatinib-resistant chronic myelocytic leukemia (CML) and many patients undergo sequential treatment. We aimed at modeling sequential tyrosine kinase inhibitor (TKI) resistance in vitro to compare the seq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a5c9d8cee2b4f8fd3318cf21200100f
https://doi.org/10.1158/1078-0432.c.6522483
https://doi.org/10.1158/1078-0432.c.6522483
PDF File - 120K, BCR-ABL kinase domain mutations recovered in the sequential screen with IC50-values for imatinib, dasatinib and nilotinib.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5479597be65e3cd8392bc335a78e7a6
https://doi.org/10.1158/1078-0432.22452459.v1
https://doi.org/10.1158/1078-0432.22452459.v1
Autor:
Justus Duyster, Christian Peschel, Jana Sänger, Espen Åberg, Richard A. Engh, Nikolas von Bubnoff
FMS-like tyrosine kinase 3 (FLT3) inhibitors have shown activity in the treatment of acute myelogenous leukemia (AML). Secondary mutations in target kinases can cause clinical resistance to therapeutic kinase inhibition. We have previously shown that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2435df97c7ff499c39fc9be5547bc9d
https://doi.org/10.1158/0008-5472.c.6499691.v1
https://doi.org/10.1158/0008-5472.c.6499691.v1
Autor:
Philip Keye, Anne Charlet, Michael Reth, Kathrin Kläsener, Max Kappenstein, Cornelia Endres, Teresa Poggio, Nikolas von Bubnoff, Anna Lena Illert, Jana Sänger, Stefanie Kreutmair, Cornelius Miething, Christoph Rummelt, Justus Duyster, Sivahari P. Gorantla
Publikováno v:
Leukemia. 36:701-711
FLT3-ITD is the most predominant mutation in AML being expressed in about one-third of AML patients and is associated with a poor prognosis. Efforts to better understand FLT3-ITD downstream signaling to possibly improve therapy response are needed. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6fb8aa8e0d51349749e9a105ed9eb4bc
https://doi.org/10.1038/s41375-021-01462-4
https://doi.org/10.1038/s41375-021-01462-4
Autor:
Anne, Charlet, Max, Kappenstein, Philip, Keye, Kathrin, Kläsener, Cornelia, Endres, Teresa, Poggio, Sivahari P, Gorantla, Stefanie, Kreutmair, Jana, Sänger, Anna L, Illert, Cornelius, Miething, Michael, Reth, Justus, Duyster, Christoph, Rummelt, Nikolas, von Bubnoff
Publikováno v:
Leukemia. 36(3)
FLT3-ITD is the most predominant mutation in AML being expressed in about one-third of AML patients and is associated with a poor prognosis. Efforts to better understand FLT3-ITD downstream signaling to possibly improve therapy response are needed. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fc07ab8d92a1337b286a0127b5c886f7
https://pubmed.ncbi.nlm.nih.gov/34750506
https://pubmed.ncbi.nlm.nih.gov/34750506
Autor:
Christian Peschel, Paul W. Manley, Jürgen Mestan, Nikolas von Bubnoff, Justus Duyster, Jana Sänger
Publikováno v:
Blood. 108:1328-1333
In advanced-phase chronic myeloid leukemia (CML), resistance to imatinib mesylate is associated with point mutations in the BCR-ABL kinase domain. A new generation of potent ABL kinase inhibitors is undergoing clinical evaluation. It is important to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bd169b14f47a3fc1f1922520c3b415d
https://doi.org/10.1182/blood-2005-12-010132
https://doi.org/10.1182/blood-2005-12-010132
Autor:
Christian Peschel, William G. Bornmann, Darren R. Veach, Nikolas von Bubnoff, Walter E. Aulitzky, Jana Sänger, Bayard D. Clarkson, Heiko van der Kuip, Petra Seipel, Justus Duyster
Publikováno v:
Blood. 105:1652-1659
In Philadelphia-positive (Ph(+)) leukemia, point mutations within the Bcr-Abl kinase domain emerged as a major mechanism of resistance to imatinib mesylate. We established a cell-based screening strategy for detection of clinically relevant point mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::677dbe9982bda5e97664d2e1b346fe24
https://doi.org/10.1182/blood-2004-06-2445
https://doi.org/10.1182/blood-2004-06-2445
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 19(11)
Purpose: Dasatinib and nilotinib are active in imatinib-resistant chronic myelocytic leukemia (CML) and many patients undergo sequential treatment. We aimed at modeling sequential tyrosine kinase inhibitor (TKI) resistance in vitro to compare the seq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87d356449810cf631cada9aa6782777e
https://pubmed.ncbi.nlm.nih.gov/23549879
https://pubmed.ncbi.nlm.nih.gov/23549879
Autor:
Jana Sänger, Nikolas von Bubnoff, Espen Åberg, Richard A. Engh, Christian Peschel, Justus Duyster
Publikováno v:
Cancer research. 69(7)
FMS-like tyrosine kinase 3 (FLT3) inhibitors have shown activity in the treatment of acute myelogenous leukemia (AML). Secondary mutations in target kinases can cause clinical resistance to therapeutic kinase inhibition. We have previously shown that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c21992199b778e9724ed11fe70c84d9
https://pubmed.ncbi.nlm.nih.gov/19318574
https://pubmed.ncbi.nlm.nih.gov/19318574
Autor:
Nikolas, von Bubnoff, Darren R, Veach, W Todd, Miller, Wanqing, Li, Jana, Sänger, Christian, Peschel, William G, Bornmann, Bayard, Clarkson, Justus, Duyster
Publikováno v:
Cancer research. 63(19)
Imatinib mesylate (STI571, Glivec), a 2-phenylaminopyrimidine small-molecule ATP competitor-type kinase inhibitor, proved to be active in Philadelphia-positive leukemias. Resistance toward imatinib develops frequently in advanced-stage Philadelphia-p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::358f6defe31bb5b0223559b5eef3dc1a
https://pubmed.ncbi.nlm.nih.gov/14559829
https://pubmed.ncbi.nlm.nih.gov/14559829